so as you stated "While both parts of the application are published and they appear as one document, it is very important to understand that it is only the claims that are actually 'patented'."
so now i guess we need to look a little closer at the claims to see if my earlier statements hold water or not. Here's my original comments:
Now, DNAG is claiming that these AIMs can be used for more than just determining biogeographical ancestry, they can be used to infer responsiveness of an individual to a drug, and predisposition of an individual to a disease. They are defining other utilities of AIMs, are they not?
Do you think others will be freely able to use AIMs or any subset of these AIMs in their own drug discovery process? Or will they need to license the rights to these AIMs from DNAG?
I would think given DNAG's ability to demonstrate the utility of ancestry statification during drug discovery/responsiveness to a drug would indeed make the AIMs DNAG's and others would be required to license them for these utilities.
i believe this is the point Dr. Frudakis (the real one, lol) was originally making in regards to the value of patenting AIMs....
well after closer examination of the claims, it appears DNAG has indeed covered drug discovery!!!
here are DNAG's claims listed in their WIPO patent application. and as i read them, companies wishing to use AIMs in drug discovery will indeed have to license them from DNAG.
FROG, after your review of the claims (or at least the ones i've highlighted for you) please provide your thoughts on my earlier statements.....it appears that DNAG has covered this critical aspect of drug discovery and disease susceptability!!! All investors should be very pleased to have this reconfirmed by the actual patent claims.
1. A plurality of primer pairs for detecting an AIM, wherein the plurality comprises at least 2 different primer pairs, wherein each pair comprises:
(a) a first primer comprising 15-50 contiguous nucleotides of a sequence set forth in SEQ ID NOs:364-537; and
(b) a second primer comprising 15-50 contiguous nucleotides of the complement of a sequence set forth in SEQ ID NOs:364-537, wherein each of the at least two different primer pairs can be used to amplify a polynucleotide comprising a nucleotide occurrence of a single nucleotide polymorphism as set forth in any of SEQ ID NOs: 364-537
2. The plurality of primer pairs of claim 1, wherein the at least 2 different primer pairs comprise sequences from a single panel, wherein the panel is selected from:
(a) panel 3: SEQ ID NOs:712-725;
(b) panel 41 : SEQ ID NOs:726-745;
(c) panel 42: SEQ ID NOs:746-759;
(d) panel 43 : SEQ ID NOs:760-777;
(e) panel 4452: SEQ ID NOs:777-825;
(f) panel 4553: SEQ ID NOs:826-867;
(g) panel 4654: SEQ ID NOs:868-907; (h) panel 4755: SEQ ID NOs:908-951; (i) panel 48: SEQ ID NOs:952-975;
(j) panel 4957: SEQ ID NOs:976-1011;
(k) panel 5051: SEQ ID NOs:1012-1041; and
(1) panel 56A: SEQ ID NOs: 1042-1059.
3. The plurality of primer pairs of claims 2, comprising:
(a) 7 primer pairs of panel 3 ;
(b) 10 primer pairs of panel 41;
(c) 7 primer pairs of panel 42;
(d) 9 primer pairs of panel 43 ;
(e) 24 primer pairs of panel 4452;
(f) 21 primer pairs of panel 4553;
(g) 20 primer pairs of panel 4654; (h) 22 primer pairs of panel 4755; (i) 12 primer pairs of panel 48 ; (j) 18 primer pairs of panel 4957; (k) 15 primer pairs of panel 5051 ; or (1) 9 primer pairs of panel 56A.
4. The plurality of primer pairs of claim 1, wherein the at least 2 primer pairs comprise sequences from at least 2 panels, wherein the 2 panels are selected from:
(a) panel 3: SEQ ID NOs:712-725;
(b) panel 41 : SEQ ID NOs:726-745;
(c) panel 42: SEQ ID NOs:746-759;
(d) panel 43: SEQ ID NOs:760-777;
(e) panel 4452: SEQ ID NOs:777-825; (i) panel 4553: SEQ ID NOs:826-867; (g) panel 4654: SEQ ID NOs:868-907; (h panel 4755: SEQ ID NOs:908-951; (i) panel 48: SEQ ID NOs:952-975;
(j) panel 4957: SEQ ID NOs:976-1011;
(k) panel 5051: SEQ ID NOs:1012-1041; and
(1) panel 56A: SEQ ID NOs: 1042-1059.
5. The plurality of primer pairs of claim 4, comprising:
(a) 7 primer pairs of panel 3;
(b) 10 primer pairs of panel 41;
(c) 7 primer pairs of panel 42;
(d) 9 primer pairs of panel 43 ;
(e) 24 primer pairs of panel 4452;
(f) 21 primer pairs of panel 4553;
(g) 20 primer pairs of panel 4654; (h) 22 primer pairs of panel 4755 ;
(i) 12 primer pairs of panel 48;
(j) 18 primer pairs of panel 4957;
(k) 15 primer pairs of panel 5051; and
(1) 9 primer pairs of panel 56 A.
6. A plurality of primers for detecting an AIM, wherein the plurality comprises at least 2 different primers, wherein each primer comprises 15-100 contiguous nucleotides of a sequence set forth in SEQ E) NOs:364-537, or 15-100 contiguous nucleotides of the complement of a sequence set forth in SEQ ID NOs:364-537, wherein each of the at least two different primers can be used to detect a nucleotide occurrence of a single nucleotide polymorphism as set forth in any of SEQ ID NOs: 364-537.
7. The plurality of primers of claim 6, wherein the at least 2 different primers comprise sequences from a single panel, wherein the panel is selected from:
(a) panel 3: SEQ ID NOs:538-544;
(b) panel 41 : SEQ ID NOs: 545-554;
(c) panel 42: SEQ TD NOs: 555-561 ;
(d) panel 43: SEQ ID NOs:562-570;
(e) panel 4452: SEQ ID NOs:571-594;
(f) panel 4553: SEQ ID NOs:595-615;
(g) panel 4654: SEQ ID NOs:616-635; (h) panel 4755: SEQ ID NOs:636-657; (i) panel 48: SEQ ID NOs:658-669; 0) panel 4957: SEQ ID NOs:670-687;
(k) panel 5051 : SEQ ID NOs:688-702; and (a) panel 56A: SEQ ID NOs:703-711.
8. The plurality of primers of claim 7, comprising:
(a) 7 primers of panel 3;
(b) 10 primers of panel 41;
(c) 7 primers of panel 42;
(d) 9 primers of panel 43 ;
(e) 24 primers of panel 4452;
(f) 21 primers of panel 4553;
(g) 20 primers of panel 4654; (h) 22 primers of panel 4755 ; (i) 12 primers of panel 48; (j) 18 primers of panel 4957; (k) 15 primers of panel 5051; or (1) 9 primers of panel 56 A.
9. The plurality of primers of claim 6, wherein the at least 2 different primers comprise sequences from at least two panels, wherein the panels are selected from:
(a) panel 3: SEQ ID NOs:538-544;
(b) panel 41 : SEQ ID NOs: 545-554;
(c) panel 42: SEQ ID NOs: 555-561;
(d) panel 43: SEQ ID NOs:562-570;
(e) panel 4452: SEQ ID NOs:571-594;
(f) panel 4553: SEQ ID NOs:595-615;
(g) panel 4654: SEQ ID NOs:616-635; (h) panel 4755: SEQ ID NOs:636-657; (i) panel 48: SEQ ID NOs:658-669; Q) panel 4957: SEQ ID NOs:670-687;
(k) panel 5051 : SEQ ID NOs:688-702; and
(1) panel 56A: SEQ ID NOs:703-711.
10. The plurality of primers of claim 9 comprising:
(a) 7 primers of panel 3;
(b) 10 primers of panel 41 ;
(c) 7 primers of panel 42;
(d) 9 primers of panel 43;
(e) 24 primers of panel 4452;
(f) 21 primers of panel 4553;
(g) 20 primers of panel 4654;
(h) 22 primers of panel 4755 ;
(i) 12 primers of panel 48 ;
(j) 18 primers of panel 4957;
(k) 15 primers of panel 5051 ; and
(1) 9 primers of panel 56 A.
11. A kit, comprising the plurality of primer pairs of any of claims 1 -5.
12. The kit of claim 11, further comprising at least one reagent for performing a DNA amplification reaction.
13. The kit of claim 12, wherein the reagent comprises at least one polymerase, deoxyribonucleotide triphosphate, deoxyribonucleotide triphosphate analog, or a combination thereof.
14. The kit of claim 13, wherein the deoxyribonucleotide triphosphate analog comprises a dideoxyribonucleotide triphosphate.
15. The kit of claim 13 , which comprises dideoxyadenosine, dideoxycytidine, dideoxyguanidine, dideoxythymidine, or a combination thereof.
16. The kit of claim 13, wherein the deoxyribonucleotide triphosphate or deoxyribonucleotide triphosphate analog comprises a detectable label.
17. A kit, comprising the plurality of primers of any of claims 6-10.
18. The kit of claim 17, further comprising at least one reagent for performing a primer extension reaction.
19. The kit of claim 18, wherein the reagent comprises at least one polymerase, deoxyribonucleotide triphosphate, deoxyribonucleotide triphosphate analog, or a combination thereof.
20. The kit of claim 19, which comprises dideoxyadenosine, dideoxycytidine, dideoxyguanidine, dideoxythymidine, or a combination thereof.
21. The kit of claim 19, wherein the deoxyribonucleotide triphosphate or deoxyribonucleotide triphosphate analog comprises a detectable label.
22. A method of inferring, with a predetermined level of confidence, a trait of an individual, comprising:
(a) contacting at least a first sample comprising test nucleic acid molecules of an individual with at least a first plurality of primers as set forth in claim 7, under conditions suitable for single base extension of the primers, and
(b) detecting at least one single base extension product of a primer of the first plurality, wherein the single base extension product is informative of a nucleotide occurrence of a single nucleotide polymorphism (SNP) of an ancestry informative marker (AIM) indicative of a population structure correlated with a trait, thereby inferring, with a predetermined level of confidence, the trait of the individual.
23. The method of claim 22, further comprising detecting single base extension products of each primer of the plurality of claim 10.
24. The method of claim 22, further comprising contacting at least a second sample comprising test nucleic acid molecules of the individual with at least a second plurality of primers as set forth in claim 7, under conditions suitable for single base extension of the primers, and detecting at least one single base extension product of a primer of the second plurality, wherein the single base extension product is informative of a nucleotide occurrence of a SNP of an AIM indicative of a population structure correlated with the trait.
25. The method of claim 22, further comprising contacting each of twelve samples comprising test nucleic acid molecules of the individual with each primer of the plurality as set forth in claim 10 under conditions suitable for single base extension of the primers, and detecting single base extension product of the primers, wherein each single base extension product is informative of a nucleotide occurrence of a SNP of an AEVI indicative of a population structure correlated with the trait.
26. The method of claim 22, wherein the single base extension product comprises a detectable label indicative of the single base.
27. The method of claim 22, wherein detecting the single base extension product is performed using electrophoresis, mass spectrometry, or gel chromatography.
28. The method of claim 27, wherein the electrophoresis comprises capillary gel electrophoresis.
29. The method of claim 22, wherein the test nucleic acid sample comprises a polymerase chain reaction amplification product.
30. The method of claim 22, wherein the trait comprises biogeo graphical ancestry (BGA).
31. The method of claim 30, wherein the BGA comprises a proportion of a sub-Saharan African, Native American, IndoEuropean, or East Asian ancestral group, or a combination of said ancestral groups.
32. The method of claim 22, wherein determination of BGA can be used to infer responsiveness of the individual to a drug.
33. The method of claim 32, wherein the drug is a cancer chemotherapeutic agent, or a statin.
34. The method of claim 22, wherein determination of BGA can be used to infer susceptibility to a disease.
35. The method of claim 34, wherein the disease has an ethnic predisposition.
36. The method of claim 22, wherein determination of BGA can be used to infer a pigmentation trait.
37. The method of claim 22, which comprises determining proportional ancestry of at least two ancestral groups of the individual.
38. The method of claim 37, which comprises determining proportional ancestry of three ancestral groups of the individual.
39. The method of claim 22, further comprising generating a graphical representation of the comparison of the three ancestral groups, said graphical representation comprising a triangle with each an ancestral group independently represented by a vertex of the triangle, wherein the maximum likelihood value of proportional affiliation for an individual comprises a point within the triangle.
40. The method of claim 39, wherein the graphical representation further comprises a confidence contour indicating a level of confidence associated with estimating the proportional ancestry.
41. A method of inferring, with a predetermined level of confidence, a trait of an individual, comprising:
(a) contacting each of 12 aliquots of a nucleic acid sample of test individual with one of each of the plurality of primer pairs of claim 5, under conditions suitable for polymerase chain reaction (PCR) amplification of target nucleotide sequences in the nucleic acid sample, thereby generating 12 PCR amplification samples;
(b) depleting each of the 12 PCR amplification samples of single stranded primers of the plurality of primer pairs and deoxyribonucleotide triphosphates;
(c) thereafter contacting each of the 12 PCR amplification samples with (i) one of each plurality of primers as set forth in claim 10, and (ii) dideoxyadenosine, dideoxycytidine, dideoxyguanidine, and dideoxythymidine, each of which comprises a different detectable label, under conditions suitable for single base extension of the primers, thereby generating 12 single base extension samples, each of which comprises a plurality of single base extension products; and
(d) detecting single base extension products in each of the 12 single base extension samples, wherein the single base extension products are informative of nucleotide occurrences of a single nucleotide polymorphisms of ancestry informative markers indicative of a population structure correlated with a trait, thereby inferring, with a predetermined level of confidence, the trait of the individual.
42. The method of claim 37, wherein detecting the single base extension products is performed using capillary gel electrophoresis.
43. A method of inferring, with a predetermined level of confidence, a trait of an individual, comprising detecting a nucleotide occurrence of a single nucleotide polymorphism as set forth in any of SEQ ID NOS: 371 to 398, 400 to 408, 410 to 413, 415, 418, 420, 422, 423, 425, 431 to 433, 438 to 441, 443, 450 to 452, 455, 456, 461 to 463, 467 to 475, 477 to 485, 487, 495 to 498, 502 to 504, 506, 508 to 512, 514, 516, 519 to 521, 526, 529, and 533 to 537, wherein the nucleotide occurrence allows an inference as to the trait.
Contact usSitemap ABOUT WIPO What is WIPO? What is IP? How WIPO works Members and Observers Program and Budget Treaties Annual Reports Recruitment Procurement IP SERVICES Patents (PCT) Trademarks (Madrid system) Designs (Hague system) Appellations of Origin (Lisbon System) Protection of State Emblems (Article 6ter) Arbitration and Mediation Center Domain name dispute resolution International Classifications PROGRAM ACTIVITIES Developing laws and standards IP for Development Copyright issues Traditional Knowledge, Genetic Resources Small and Medium-sized Enterprises WIPO Academy Public Outreach Promoting innovation Enforcement of IP Rights RESOURCES E-Bookshop Free Publications Documents Search IP Databases Library Collection of Laws (CLEA) Directory of IP Offices IP Statistics WIPO Standards FAQs NEWS & EVENTS Press room WIPO Magazine Calendar Meetings, Seminars World IP Day E-mail newsletters RSS News Feed HomeIP ServicesPatentScopePatent Search Patent Search Home About Patents Patent Search Content Terms & Conditions Glossary Other Collections PCT Resources PCT Electronic Filing Patent & Technical Information Statistics Law of Patents Meetings Contact Related Links International Patent Classification Natural Language IPC Search Standards & Documentation E-NEWSLETTERS Subscribe to receive e-mails of news and updates on WIPO's activities regarding patents and the PCT
News 
Market Data 
Discover 
AI
